Anacor Pharmaceuticals Inc (ANAC)

99.20
0.03 0.03
Prev Close 99.17
Open 99.22
Day Low/High 99.20 / 99.27
52 Wk Low/High 52.00 / 156.93
Volume 5.37M
Avg Volume 2.55M
Exchange
Shares Outstanding 45.37M
Market Cap 4.50B
EPS -1.40
Div & Yield N.A. (N.A)

Latest News

Will Pfizer Book Another Healthy Quarter?

Will Pfizer Book Another Healthy Quarter?

Pfizer shares are up 13% year to date, and the company reports earnings on Aug. 2. Here's what to expect.

Biotech M&A Waking Up After Long Nap

The uptick in the small- and mid-cap space bodes well for future capital appreciation.

Buy Pfizer, Chevron, Newell Brands and Enjoy the Profits

Buy Pfizer, Chevron, Newell Brands and Enjoy the Profits

Tom Forester, portfolio manager for the Forester Value Fund, said Pfizer's ability to make deals is only one reason why this stock will make you money.

Why Pfizer, Chevron and Newell Brands Could be Great For Your Portfolio

Why Pfizer, Chevron and Newell Brands Could be Great For Your Portfolio

Pfizer has dominated headlines this year with its failed Allergan merger and its Anacor Pharmaceuticals purchase.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation Of The Board Of Directors Of Anacor Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation Of The Board Of Directors Of Anacor Pharmaceuticals, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Anacor Pharmaceuticals, Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Into Whether The Sale Of Anacor Pharmaceuticals, Inc. To Pfizer Inc. For $99.25 Per Share Is Fair To Shareholders

INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Into Whether The Sale Of Anacor Pharmaceuticals, Inc. To Pfizer Inc. For $99.25 Per Share Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Anacor Pharmaceuticals, Inc.

ANACOR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces The Investigation Of Anacor Pharmaceuticals, Inc. (ANAC) Over The Proposed Sale Of The Company To Pfizer Inc.

ANACOR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces The Investigation Of Anacor Pharmaceuticals, Inc. (ANAC) Over The Proposed Sale Of The Company To Pfizer Inc.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Anacor Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Regarding The Fairness Of The Sale Of Anacor Pharmaceuticals, Inc. To Pfizer Inc. For $99.25 Per Share

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Regarding The Fairness Of The Sale Of Anacor Pharmaceuticals, Inc. To Pfizer Inc. For $99.25 Per Share

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Anacor Pharmaceuticals, Inc.

FOMC Scare Enhances Buying Opportunities

We have room for 3 new names in the portfolio if weakness persists.

Anacor Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Merger With Pfizer, Inc.

Anacor Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Merger With Pfizer, Inc.

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Anacor...

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Anacor Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Anacor Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Anacor...

Regeneron's Spike Not Tied to Pfizer-Anacor Deal, but It Doesn't Hurt

Regeneron's Spike Not Tied to Pfizer-Anacor Deal, but It Doesn't Hurt

Dupilumab, an eczema therapy awaiting FDA approval, is arguably the most important pipeline drug for Regeneron.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Anacor Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Anacor Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Anacor...

Stocks Enjoy Monday Rally as Apple Sees Best Gains in Four Months

Stocks Enjoy Monday Rally as Apple Sees Best Gains in Four Months

Apple reclaims its crown as the world's largest company after a Warren Buffett-inspired rally pulled the company back from last week's doldrums.

Stocks at Session Highs as Apple and Crude Oil Jump

Stocks at Session Highs as Apple and Crude Oil Jump

Stocks begin the week with a rally, climbing to session highs by Monday afternoon, as Apple jumps and crude oil hits a six-month high.

Jim Cramer -- Quick Take on 30 Stocks and What Investors Are Missing

Jim Cramer -- Quick Take on 30 Stocks and What Investors Are Missing

This is the final of a two-part series in which Jim Cramer comments on each of the 30 Dow components.

Trending Tickers: IBM, AAPL, WMT, YHOO

Crude prices were helping lift U.S. markets. 

Pfizer Beats Allergan to Eczema Drugmaker Anacor for $5.2B

Pfizer Beats Allergan to Eczema Drugmaker Anacor for $5.2B

The deal gives the acquirer access to Crisaborole and denies the excema drug to its ex-merger partner.

Jim Cramer: Pfizer Will Have a Long Road Ahead With Anacor Buy

Jim Cramer: Pfizer Will Have a Long Road Ahead With Anacor Buy

Jim Cramer says he wouldn't be surprised if Allergan looked at buying Anacor before Pfizer decided to acquire the company for $5.2 billion, including debt.

Stocks Extend Gains as Apple Enjoys Best Day in Six Weeks

Stocks Extend Gains as Apple Enjoys Best Day in Six Weeks

Stocks extend gains on Monday morning as Warren Buffett's Berkshire Hathaway discloses a stake in Apple worth nearly $900 million.

Opening Bell: Stocks Open Higher on Oil Gains, China Posts Weak Retail Sales

Opening Bell: Stocks Open Higher on Oil Gains, China Posts Weak Retail Sales

U.S. stocks opened higher on Monday, amid rising oil prices.

Stock Futures Turn Mixed Despite Apple Gains

Stock Futures Turn Mixed Despite Apple Gains

Stock futures turn mixed Monday morning as Warren Buffett's Berkshire Hathaway discloses a stake in Apple worth nearly $900 million.